LOS ANGELES, Calif. (September 10, 2015) — Tomorrow, renowned eye surgeon, Dr. Kerry Assil will perform surgery on the last two patients, who will be enrolled in the final phase of the Presbia Flexiuve Microlens™ as part of an FDA study. The study began last year, when he was the first to implant the lens. The Presbia Flexivue Microlens is a revolutionary optical lens implant designed to treat presbyopia – the age-related loss of near Vision – and has been commercially available in Europe and other countries around the world where it has obtained regulatory approval.
Dr. Assil, who is at the forefront of research and technology in eye surgery, was one of the first surgeons in the world, to implant the Microlens (overseas), nearly 15 years ago. The Presbia Flexivue Microlens is a microscopic implant made of hydrophilic acrylic and shaped like a contact lens. It is implanted in the cornea of the eye using the same type of laser used in LASIK procedures. Once inserted, it enables the eye to see both near and far.
“Having successfully inserted the Presbia Microlens in patients outside of the U.S., it’s very exciting to see the conclusion of our U.S. FDA patient enrollment,” said Dr. Assil. “The Microlens appears to be a promising Presbyopia correcting technology, as unlike other alternatives, it can profoundly improve the near vision, without significantly affecting distance clarity.”